NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
6/8 — Strong
WELLBUTRIN SR (bupropion hydrochloride) by GSK is unknown, as is the case with other antidepressants. Approved for major depressive disorder, smoking cessation, seasonal affective disorder. First approved in 1996.
WELLBUTRIN SR is an extended-release oral tablet formulation of bupropion hydrochloride, approved in 1996 for major depressive disorder and seasonal affective disorder. It works through presumed noradrenergic and dopaminergic mechanisms, weakly inhibiting neuronal reuptake of norepinephrine and dopamine without affecting serotonin or monoamine oxidase. This unique mechanism differentiates it from SSRIs and other conventional antidepressants.
$0.006BPart D
LOE ApproachingDeclining revenue and approaching loss of exclusivity signal mature-stage brand management with focus on cost containment and generic transition planning.
Mechanism of Action
unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the…
Indications (3)
Worked on WELLBUTRIN SR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.